CEN-101: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
|||
| Line 22: | Line 22: | ||
StaphOff developed CEN-101 (also known as RIP or RNAIII Inhibiting Peptide), the first treatment for staph whose mechanism of action IS NOT to kill the bacteria. Rather, it eliminates the ability of these bacteria to form biofilms, to produce toxins and to survive. The molecule is a heptapeptide that can be delivered by a variety of dosing methods: (1) topical, (2) locally injectable, (3) intravenous administration, and (4) in solution as a medical device coating or in sterile locks. | StaphOff developed CEN-101 (also known as RIP or RNAIII Inhibiting Peptide), the first treatment for staph whose mechanism of action IS NOT to kill the bacteria. Rather, it eliminates the ability of these bacteria to form biofilms, to produce toxins and to survive. The molecule is a heptapeptide that can be delivered by a variety of dosing methods: (1) topical, (2) locally injectable, (3) intravenous administration, and (4) in solution as a medical device coating or in sterile locks. | ||
A large body of compelling evidence exists demonstrating that CEN-101 is effective in preventing and curing staph infections. In vitro data have been published in 8 peer reviewed articles. Twenty (20) peer reviewed animal studies have been published for rats, mice, cows, and rabbits, all demonstrating that CEN-101 works effectively in a variety of applications (wound infections, graft associated infections, cellulitis, arthritis, sepsis, osteomyelitis and mastitis) with no observable side effects. Three (3) articles about compassionate use in humans have also been published. All are part of a 323 patient compassionate care study of topical CEN-101, with a overall 91% improvement in outcome in advanced stage wound care patients (reduced number of amputations and reduced number of sepsis-related deaths). | A large body of compelling evidence exists demonstrating that CEN-101 is effective in preventing and curing staph infections. In vitro data have been published in 8 peer reviewed articles. Twenty (20) peer reviewed animal studies have been published for rats, mice, cows, and rabbits, all demonstrating that CEN-101 works effectively in a variety of applications (wound infections, graft associated infections, cellulitis, arthritis, sepsis, osteomyelitis and mastitis) with no observable side effects. Three (3) articles about compassionate use in humans have also been published. All are part of a 323 patient compassionate care study of topical CEN-101, with a overall 91% improvement in outcome in advanced stage wound care patients (reduced number of amputations and reduced number of sepsis-related deaths) | ||
<ref name="Lopez-Leban">PMID: 20963725</ref>. | |||
. | |||
=References= | =References= | ||
<references/> | <references/> | ||
